Nasdaq Listing Compliance Sample Clauses

Nasdaq Listing Compliance. Common shares of the Company's Common Stock are registered pursuant to Section 12(g) of the Exchange Act and are listed on the Nasdaq National Market and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or de-listing the Common Stock from the Nasdaq National Market, nor has the Company received any notification that the Commission or Nasdaq, Inc. is contemplating terminating such registration or listing.
Sample 1Sample 2See All (6)
AutoNDA by SimpleDocs
Nasdaq Listing Compliance. The Company's Common Stock is registered pursuant to Section 12(g) of the Exchange Act and is listed on the Nasdaq Small Cap Market and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or de-listing the Common Stock from the Nasdaq Small Cap Market. In addition, except for the correspondence from NASDAQ to the Company on August 20, 2002, a copy of which has been previously provided to the Purchaser, the Company has not received any notification from the Commission or NASDAQ indicating that the Company is subject to or in risk of being delisted from the Nasdaq SmallCap Market.
Sample 1Sample 2
Nasdaq Listing Compliance. The BioMarin Common Stock is registered pursuant to Section 12(g) of the Exchange Act and is listed on the Nasdaq National Market or any United States national securities exchange and BioMarin has taken no action designed to, or likely to have the effect of, terminating the registration of the BioMarin Common Stock under the Exchange Act or de-listing the BioMarin Common Stock from the Nasdaq National Market or any United States national securities exchange, nor has BioMarin received any notification that the SEC or Nasdaq, Inc. is contemplating terminating such registration or listing.
Sample 1Sample 2
Nasdaq Listing Compliance. Please see disclosure regarding filing of "Notification Form: Listing of Additional Shares" in Schedule 5.7 to this Annex D. Schedule 5.21 Compliance with Nasdaq Requirements Please see disclosure regarding filing of "Notification Form: Listing of Additional Shares" in Schedule 5.7 to this Annex D. ANNEX E FORM OF LEGAL OPINION May 16, 2001 THE INVESTORS NAMED IN THE SECURITIES PURCHASE AGREEMENT DESCRIBED BELOW Re: BioMarin Pharmaceutical Inc. Ladies and Gentlemen: We have acted as counsel for BioMarin Pharmaceutical Inc., a Delaware corporation (the "Company"), in connection with that certain Securities Purchase Agreement (the "Purchase Agreement") dated May 16, 2001 by and among the Company and those Investors listed on Annex A to the Purchase Agreement (the "Investors"). This opinion is being furnished to you pursuant to Section 6.1(d) of the Purchase Agreement. The Purchase Agreement provides for the sale and issuance by the Company to the Investors of 4,763,712 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), and warrants (the "Warrants") for the purchase of 714,554 shares of Common Stock (the "Warrant Stock"). All capitalized terms used herein and not defined herein shall have the meanings ascribed to them in the Purchase Agreement. For purposes of our opinions set forth below, we have made such legal and factual examinations and inquiries as we have deemed advisable or necessary. As to matters of fact relevant to this opinion, we have relied upon (i) certificates of officers of the Company delivered on the Closing Date, (ii) the representations and warranties of the Company set forth in the Purchase Agreement, and (iii) statements made by public officials in certificates delivered to us on or before the Closing Date. In addition, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such agreements, instruments and certificates of public officials, certificates of officers or other representatives of the Company and others, and such other documents, certificates and records as we deemed necessary or appropriate for the purpose of rendering this opinion. In such examination, we have assumed the genuineness of all signatures on original documents, the authenticity of all documents submitted to us as originals, and the conformity to original documents of all copies submitted to us as copies thereof. For purposes of this opinio...
Sample 1
Nasdaq Listing Compliance. 15 3.13 Investment Representations of BioMarin............................................... 15 3.14 Absence of Changes................................................................... 16
Sample 1
Nasdaq Listing Compliance. The Common Stock is registered pursuant to Section 12(g) of the Exchange Act of 1934, as amended (the "Exchange Act") and is approved for quotation on the Nasdaq Small Cap Market. The Company has taken no action designed to (or likely to have the effect of) result in a termination the registration of the Common Stock under the Exchange Act or a de-listing of the Common Stock from the Nasdaq Small Cap Market, nor has the Company received, nor has it any reason to believe it will receive, any notification that the Securities and Exchange Commission (the "Commission") or Nasdaq, Inc. is contemplating terminating such registration or listing.
Sample 1
Nasdaq Listing Compliance. The Common Stock shall remain registered pursuant to Section 12(b) of the 1934 Act and listed on the Nasdaq.
Sample 1
AutoNDA by SimpleDocs

Related to Nasdaq Listing Compliance

  • Nasdaq Listing The shares of Parent Common Stock to be issued in the Merger shall have been authorized for listing on Nasdaq, subject to notice of issuance.

  • Nasdaq Compliance The Company's Common Stock is registered pursuant to Section 12(g) of the Exchange Act and is listed on The Nasdaq Stock Market, Inc. National Market (the "Nasdaq National Market"), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or de-listing the Common Stock from the Nasdaq National Market, nor has the Company received any notification that the Securities and Exchange Commission (the "SEC") or the NASD is contemplating terminating such registration or listing.

  • Stock Exchange Listing The shares of Common Stock have been approved for listing on the NASDAQ Capital Market (the “Exchange”), and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the Exchange, nor has the Company received any notification that the Exchange is contemplating terminating such listing except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

  • Exchange Listing The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be, shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance.

  • NYSE Listing The shares of Parent Common Stock to be issued to the holders of Company Common Stock upon consummation of the Merger shall have been authorized for listing on the NYSE, subject to official notice of issuance.

  • Stock Exchange Listings Parent shall use all reasonable efforts to list on the NYSE, upon official notice of issuance, the Paired Shares to be issued in connection with the Merger.

  • SEC Compliance Such Borrower and the applicable Fund(s) are in compliance in all material respects with all federal and state securities or similar laws and regulations, including all material rules, regulations and administrative orders of the Securities and Exchange Commission (the "SEC") and applicable Blue Sky authorities. Such Borrower and the applicable Fund(s) are in compliance in all material respects with all of the provisions of the Investment Company Act of 1940, and such Borrower has filed all reports with the SEC that are required of it or the applicable Fund(s);

  • Reporting Compliance The Company is subject to, and is in compliance in all material respects with, the reporting requirements of Section 13 and Section 15(d), as applicable, of the Exchange Act.

  • AMEX Listing The Public Securities shall have been approved for listing on AMEX.

  • Obtaining Stock Exchange Listings The Company will from time to time take all commercially reasonable actions which may be necessary so that the Warrant Shares, immediately upon their issuance upon the exercise of Warrants, will be listed on the principal securities exchanges and markets within the United States of America, if any, on which other shares of Common Stock are then listed.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!